Low-dose Hsp 90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy

Cell Cycle

Volumn 10, Issue 24, 2011, Pages 4291-4299

  Yoshida, Soichiro ^a   Koga, Fumitaka ^a   Tatokoro, Manabu ^a   Kawakami, Satoru ^a   Fujii, Yasuhisa ^a   Kumagai, Jiro ^a   Neckers, Len ^a   Kihara, Kazunori ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

17 (Dimethylaminoethylamino) 17 demethoxygeldanamycin; 17 (Allylamino) 17 demethoxygeldanamycin; Combined modality therapy; HSP90 heat shock proteins; Radiotherapy; Urinary bladder neoplasms

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 90 INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE B; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; 17-(DIMETHYLAMINOETHYLAMINO)-17-DEMETHOXYGELDANAMYCIN; ALVESPIMYCIN; BENZOQUINONE DERIVATIVE; ERBB2 PROTEIN, HUMAN; HEAT SHOCK PROTEIN 90; MACROCYCLIC LACTAM; RADIOSENSITIZING AGENT; TANESPIMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CHEMORADIOTHERAPY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; TUMOR XENOGRAFT; ANIMAL; BLADDER TUMOR; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOBLOTTING; METHODOLOGY; NONPARAMETRIC TEST; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BENZOQUINONES; CELL LINE, TUMOR; CHEMORADIOTHERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENT ANTIBODY TECHNIQUE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOBLOTTING; LACTAMS, MACROCYCLIC; MICE; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION-SENSITIZING AGENTS; RECEPTOR, ERBB-2; STATISTICS, NONPARAMETRIC; URINARY BLADDER NEOPLASMS;

EID: 84055190677     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.10.24.18616     Document Type: Article

References (46)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010; 60:277-300; PMID:20610543; http://dx.doi.org/10.3322/caac.20073.
2. Lee R, Droller MJ. The natural history of bladder cancer. Implications for therapy. [vii.]. Urol Clin North Am 2000; 27:1-13; PMID:10696240; http://dx.doi. org/10.1016/S0094-0143(05)70229-9.
3. Rödel C, Weiss C, Sauer R. Trimodality treatment and selective organ preservation for bladder cancer. J Clin Oncol 2006; 24:5536-44; PMID:17158539; http:// dx.doi.org/10.1200/JCO.2006.07.6729.
4. Koga F, Yoshida S, Kawakami S, Kageyama Y, Yokoyama M, Saito K, et al. Low-dose chemoradiotherapy followed by partial or radical cystectomy against muscle-invasive bladder cancer: an intentto- treat survival analysis. Urology 2008; 72:384-8; PMID:18455771; http://dx.doi.org/10.1016/j.urology. 2008.03.017.
5. Rödel C, Grabenbauer GG, Kuhn R, Papadopoulos T, Dunst J, Meyer M, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 2002; 20:3061-71; PMID:12118019; http://dx.doi. org/10.1200/JCO.2002.11.027.
6. Shipley WU, Prout GR Jr, Einstein AB, Coombs LJ, Wajsman Z, Soloway MS, et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 1987; 258:931- 5; PMID:3613023; http://dx.doi.org/10.1001/ jama.258.7.931.
7. Koga F, Kihara K, Yoshida S, Yokoyama M, Saito K, Masuda H, et al. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients. BJU Int 2011; In press; PMID:21854531; http://dx.doi. org/10.1111/j.1464-410X.2011.10425.x.
8. Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, Parliament M, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscleinvading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005; 62:309-17; PMID:15890569; http://dx.doi.org/10.1016/j.ijrobp.2004.09.047.
9. Izzo JG, Malhotra U, Wu TT, Ensor J, Luthra R, Lee JH, et al. Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 2006; 24:748-54; PMID:16401681; http:// dx.doi.org/10.1200/JCO.2005.03.8810.
10. Brunner TB, Geiger M, Grabenbauer GG, Lang- Welzenbach M, Mantoni TS, Cavallaro A, et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2008; 26:2699-706; PMID:18509182; http://dx.doi. org/10.1200/JCO.2007.15.2355.
11. Koga F, Yoshida S, Tatokoro M, Kawakami S, Fujii Y, Kumagai J, et al. ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer. PLoS one 2011; 6:e27616. doi:10.1371/ journal.pone.0027616.
12. Horton JK, Halle J, Ferraro M, Carey L, Moore DT, Ollila D, et al. Radiosensitization of Chemotherapy- Refractory, Locally Advanced or Locally Recurrent Breast Cancer with Trastuzumab: A Phase II Trial. Int J Radiat Oncol Biol Phys 2010; 76:998-1004; PMID:19560883; http://dx.doi.org/10.1016/j. ijrobp.2009.03.027.
13. Powers MV, Jones K, Barillari C, Westwood I, van Montfort RL, Workman P. Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone? Cell Cycle 2010; 9:1542- 50; PMID:20372081; http://dx.doi.org/10.4161/ cc.9.8.11204.
14. Koga F, Kihara K, Neckers L. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res 2009; 29:797-807; PMID:19414312.
15. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70; PMID:10647931; http:// dx.doi.org/10.1016/S0092-8674(00)81683-9.
16. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010; 10:537-49; PMID:20651736; http://dx.doi.org/10.1038/nrc2887.
17. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA 1994; 91:8324-8; PMID:8078881; http:// dx.doi.org/10.1073/pnas.91.18.8324.
18. Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14:2901-7; PMID:8918486.
19. Koga F, Kihara K, Fujii Y, Yoshida S, Saito K, Masuda H, et al. Favourable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs. immediate radical cystectomy: a singleinstitutional retrospective comparative study. BJU Int 2009; 104:189-94; PMID:19154452; http://dx.doi. org/10.1111/j.1464-410X.2008.08297.x.
20. Sawada M, Okudaira Y, Matsui Y, Nishiura H, Yanagida T. Pharmacokinetics of cis-platinum diammine dichloride. Gan To Kagaku Ryoho 1982; 9:55- 65; PMID:6892192.
21. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, Markovina S, et al. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 2003; 63:8984-95; PMID:14695217.
22. Bull EE, Dote H, Brady KJ, Burgan WE, Carter DJ, Cerra MA, et al. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)- 17-demethoxygeldanamycin. Clin Cancer Res 2004; 10:8077-84; PMID:15585643; http://dx.doi. org/10.1158/1078- 0432.CCR-04-1212.
23. Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res 2003; 9:3749-55; PMID:14506167.
24. Ahn JY, Liu X, Liu Z, Pereira L, Cheng D, Peng J, et al. Nuclear Akt associates with PKC-phosphorylated Ebp1, preventing DNA fragmentation by inhibition of caspase-activated DNase. EMBO J 2006; 25:2083- 95; PMID:16642037; http://dx.doi.org/10.1038/ sj.emboj.7601111.
25. Borgatti P, Martelli AM, Tabellini G, Bellacosa A, Capitani S, Neri LM. Threonine 308 phosphorylated form of Akt translocates to the nucleus of PC12 cells under nerve growth factor stimulation and associates with the nuclear matrix protein nucleolin. J Cell Physiol 2003; 196:79-88; PMID:12767043; http:// dx.doi.org/10.1002/jcp.10279.
26. Neri LM, Borgatti P, Capitani S, Martelli AM. The nuclear phosphoinositide-3-kinase/AKT pathway: a new second messenger system. Biochim Biophys Acta 2002; 1584:73-80; PMID:12385889.
27. Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 1998; 94:471-80; PMID:9727490; http://dx.doi. org/10.1016/S0092-8674(00)81588-3.
28. Koga F, Xu W, Karpova TS, McNally JG, Baron R, Neckers L. Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation. Proc Natl Acad Sci USA 2006; 103:11318- 22; PMID:16844778; http://dx.doi.org/10.1073/ pnas.0604705103.
29. Subjeck JR, Repasky EA. Heat shock proteins and cancer therapy: the trail grows hotter! Oncotarget 2011; 2:433-4; PMID:21677361.
30. Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM. Comparison of 17-dimethylaminoethylamino- 17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 2005; 56:126-37; PMID:15841378; http://dx.doi. org/10.1007/s00280-004-0947-2.
31. Beloueche-Babari M, Arunan V, Jackson LE, Perusinghe N, Sharp SY, Workman P, et al. Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition. Oncotarget 2010; 1:185-97; PMID:21037799.
32. Stoeltzing O. Dual-targeting of mTOR and HSP90 for cancer therapy: facing oncogenic feed-back-loops and acquired mTOR resistance. Cell Cycle 2010; 9:2051- 2; PMID:20505332; http://dx.doi.org/10.4161/ cc.9.11.11924.
33. Kyndi M, Sorensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J. Estrogen receptor, progesterone receptor, HER-2 and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol 2008; 26:1419-26; PMID:18285604; http:// dx.doi.org/10.1200/JCO.2007.14.5565.
34. Borgatti P, Martelli AM, Bellacosa A, Casto R, Massari L, Capitani S, et al. Translocation of Akt/PKB to the nucleus of osteoblast-like MC3T3-E1 cells exposed to proliferative growth factors. FEBS Lett 2000; 477:27- 32; PMID:10899305; http://dx.doi.org/10.1016/ S0014-5793(00)01758-0.
35. Fellin G, Graffer U, Bolner A, Ambrosini G, Caffo O, Luciani L. Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study. Br J Urol 1997; 80:44-9; PMID:9240179; http:// dx.doi.org/10.1046/j.1464-410X.1997.00221.x.
36. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005; 23:4152-61; PMID:15961763; http://dx.doi.org/10.1200/JCO.2005.00.612.
37. Goetz MP, Toft D, Reid J, Ames M, Stensgard B, Safgren S, et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005; 23:1078-87; PMID:15718306; http://dx.doi.org/10.1200/ JCO.2005.09.119.
38. Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007; 25:5410-7; PMID:18048823; http:// dx.doi.org/10.1200/JCO.2007.11.7960.
39. Ramanathan RK, Egorin MJ, Eiseman JL, Ramalingam S, Friedland D, Agarwala SS, et al. Phase I and pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res 2007; 13:1769-74; PMID:17363531; http://dx.doi.org/10.1158/1078-0432. CCR-06-2233.
40. Ramalingam SS, Egorin MJ, Ramanathan RK, Remick SC, Sikorski RP, Lagattuta TF, et al. A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. Clin Cancer Res 2008; 14:3456-61; PMID:18519777; http://dx.doi.org/10.1158/1078-0432. CCR-07-5088.
41. Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005; 23:1885-93; PMID:15774780; http://dx.doi. org/10.1200/JCO.2005.12.085.
42. Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, Neckers L, et al. Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 2009; 9:1479-92; PMID:19860730; http://dx.doi. org/10.2174/156802609789895728.
43. Mollapour M, Tsutsumi S, Kim YS, Trepel J, Neckers L. Casein kinase 2 pho\sphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity. Oncotarget 2011; 2:407-17; PMID:21576760.
44. Kawakami S, Arai G, Hayashi T, Fujii Y, Xia G, Kageyama Y, et al. PPARgamma ligands suppress proliferation of human urothelial basal cells in vitro. J Cell Physiol 2002; 191:310-9; PMID:12012326; http:// dx.doi.org/10.1002/jcp.10099.
45. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006; 1:2315-9; PMID:17406473; http:// dx.doi.org/10.1038/nprot.2006.339.
46. Koga F, Tsutsumi S, Neckers LM. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell Cycle 2007; 6:1393-402; PMID:17525527; http://dx.doi. org/10.4161/cc.6.11.4296.